A5022116349- Malaria Research and Control
- vaccines and immunoinformatics approaches
- Mosquito-borne diseases and control
- COVID-19 Clinical Research Studies
- Vector-borne infectious diseases
- Invertebrate Immune Response Mechanisms
- SARS-CoV-2 and COVID-19 Research
- HIV Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Virology and Viral Diseases
General Dynamics (United States)
2025
Naval Medical Research Command
2020-2025
Jackson Foundation
2020-2021
Henry M. Jackson Foundation
2020-2021
Background A three-antigen DNA-prime/chimpanzee adenovirus 63 (ChAd63) boost vaccine containing pre-erythrocytic Plasmodium falciparum (Pf) circumsporozoite protein (CSP), Pf apical membrane antigen-1 (AMA1) and malaria multiple epitopes (ME) fused to thrombospondin-related adhesion (ME-TRAP) elicited higher efficacy (VE) in an open label, randomized Phase 1 trial against controlled human infection (CHMI) than the two-antigen DNA/Human Adenovirus 5 (HuAd5) CSP AMA1. The objective of this...
Background Immunization with radiation-attenuated sporozoites (RAS) by mosquito bite provides >90% sterile protection against Plasmodium falciparum (Pf) malaria in humans. RAS invade hepatocytes but do not replicate. CD8+ T cells recognizing parasite-derived peptides on the surface of infected are likely primary protective mechanism. We conducted a randomized clinical trial immunization to assess safety, achieve 50% vaccine efficacy (VE) controlled human infection (CHMI), and generate...
Background A DNA-prime/human adenovirus serotype 5 (HuAd5) boost vaccine encoding Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) and Pf apical membrane antigen-1 (PfAMA1), elicited protection in 4/15 (27%) of subjects against controlled human malaria infection (CHMI) that was statistically associated with CD8+ T cell responses. Subjects high level pre-existing immunity to HuAd5 were not protected, suggesting an adverse effect on efficacy (VE). We replaced chimpanzee 63 (ChAd63),...
A malaria vaccine with high efficacy and capable of inducing sterile immunity against within genetically diverse populations is urgently needed to complement ongoing disease control elimination efforts. Parasite-specific IFN-γ granzyme B-secreting CD8 + T cells have been identified as key mediators protection the rapid identification antigen targets that elicit these responses will fast-track development simpler, cost-effective interventions. This study extends our previous work which used...
Only a small fraction of the antigens expressed by malaria parasites have been evaluated as vaccine candidates. A successful subunit will likely require multiple antigenic targets to achieve broad protection with high protective efficacy. Here we describe efficacy novel antigen, Plasmodium yoelii (Py) E140 (PyE140), against P. challenge mice. Vaccines targeting PyE140 reproducibly induced up 100% sterile in both inbred and outbred murine models. Although immunization frequency...
Background Immunization with radiation-attenuated sporozoites (RAS) by mosquito bites provides >90% sterile protection against Plasmodium falciparum malaria in humans. We conducted a clinical trial based on data from previous RAS trials that suggested 800–1200 infected should induce ~50% protective vaccine efficacy (VE) controlled human infection (CHMI) administered three weeks after the final immunization. Two cohorts were immunized separately. VE was 55% Cohort 1 but 90% 2, cohort...
SARS-CoV-2 T cell responses are associated with COVID-19 recovery, and Class I- II-restricted epitopes have been identified in the spike (S), nucleocapsid (N) membrane (M) proteins others. This prospective Health Action Response for Marines (CHARM) study enabled assessment of against S, N M symptomatic asymptomatic infected participants. At enrollment all participants were negative by qPCR; follow-up occurred biweekly bimonthly next 6 weeks. Study who tested positive qPCR test enrolled an...
A malaria vaccine with high efficacy and capable of inducing sterile immunity against within genetically diverse populations is urgently needed to complement ongoing disease control elimination efforts. Parasite-specific IFN-γ granzyme B-secreting CD8+ T cells have been identified as key mediators protection the rapid identification antigen targets that elicit these responses will fast-track development simpler, cost-effective interventions. This study extends our previous work which used...
ABSTRACT SARS-CoV-2 T cell responses are associated with COVID-19 recovery, and Class I- II-restricted epitopes have been identified in the spike (S), nucleocapsid (N) membrane (M) proteins others. This prospective Health Action Response for Marines (CHARM) study enabled assessment of symptomatic asymptomatic infected participants. At enrollment all participants were negative by qPCR; follow-up occurred biweekly then bimonthly next 6 weeks. Study who tested positive qPCR test asked to enroll...